

OHSU KNIGHT CARDIOVASCULAR INSTITUTE

OHSU Accepting Patients for MitraClip® Mitral Valve Repair

A word from the directors of the Complex Heart Valve Program

The OHSU Knight Cardiovascular Institute is currently accepting patients for mitral valve repair with the FDA-approved MitraClip® percutaneous mitral valve repair system.

Historically we have managed patients with mitral valve disease with repair, replacement or balloon dilation, tailoring the procedure to best fit the patient's needs. MitraClip adds an additional option for these patients.

Our team treats a wide range of patients with complex heart valve disease. We have vast experience with transcatheter aortic valve replacement (TAVR) and have recently added the CoreValve device to our program. Additionally, we have a long history of percutaneous treatment of structural heart disease including the "Melody" transcatheter pulmonary valve), percutaneous ventricular assist devices (Impella and Tandem Heart), valvuloplasties, PFO and ASD closures, ethanol septal ablations and other advanced interventional and surgical techniques.

If you have any questions or would like to consult with our team, please feel free to call us at **800 245-6478**.

Sincerely,

Saurabh Gupta, M.D.
Matt Slater, M.D.

Introduction to the MitraClip Clip Delivery System (MitraClip CDS)

The MitraClip Clip Delivery System (MitraClip CDS) is a permanent implant that attaches to the mitral valve leaflets: It is inserted by a catheter through the femoral vein and guided into the heart, where it is positioned by grasping both leaflets of the mitral valve.

This procedure allows greater closure and reduces the leakiness of the valve.

Indications for use

The MitraClip CDS is intended to treat patients with significant symptomatic degenerative mitral regurgitation with MR \geq 3+ who are at high risk for cardiac surgery.

Benefits

The major clinical benefit of the MitraClip is the reduction of mitral regurgitation. Other benefits may include:

- Fewer hospitalizations
- Improved quality of life
- Reverse left ventricular remodeling
- Symptomatic relief

Contraindications

MitraClip is contraindicated in patients with degenerative mitral valve regurgitation who meet the following conditions:

- Inability to tolerate procedural anticoagulation or post-procedural anti-platelet regimen
- Active endocarditis of the mitral valve
- Rheumatic mitral valve disease
- Evidence of intracardiac, inferior vena cava (IVC) or femoral venous thrombus

www.ohsuknightheart.com

The knowledge of all for the care of **one**.

CAR 3068267 4/14

OHSU KNIGHT CARDIOVASCULAR INSTITUTE

OHSU Accepting Patients for MitraClip® Mitral Valve Repair

About the Complex Heart Valve Program at OHSU

The Complex Heart Valve Program specializes in caring for patients with advanced heart valve disease. Our multidisciplinary team is composed of sub-specialty cardiologists and cardiac surgeons with focussed expertise in valvular heart disease. The heart valve team extends into the OHSU hospital system, where cardiovascular anesthesiologists, cardiac nurses, and critical care specialists all work together to care for patients with valvular heart disease. Throughout the clinic visits, hospitalization or procedures, we are committed to keeping the patients' primary care physician and primary cardiologist up to date.

We care for high-risk patients and/or those who require complex care or who have existing health concerns in addition to cardiac issues. An interventional cardiologist and cardiac surgeon assess patients jointly, along with an on-site heart valve team that includes ICU, cardiothoracic surgery, cardiac imaging and cardiac anesthesia. Having relevant specialties all in one place allows the team to formulate a patient's treatment plan within a single visit, which is then communicated to the patients and referring providers. A patient care coordinator manages patient appointments.

CMS coverage

The Centers for Medicare & Medicaid Services (CMS) covers MitraClip CDS for the treatment of mitral valve regurgitation:

- When used for the FDA-approved indication for treatment of degenerative mitral regurgitation in patients at high risk for cardiac surgery
- Participation in the COAPT (Clinical Outcomes Assessment of the MitraClip Percutaneous Therapy for Patients with Heart Failure and Functional Mitral Valve Regurgitation) clinical trial at OHSU

OHSU's Heart Valve team

Coordinated, state-of-the-art multidisciplinary evaluation and care provided by disciplines including cardiac surgery, interventional cardiology, cardiac imaging and interventional radiology.




Joaquin E. Cigarroa, M.D.
Interventional
Cardiology



Saurabh Gupta, M.D., F.A.C.C.
Interventional Cardiology




Stephen Heitner, M.D.
Cardiovascular
Imaging



Matt Slater, M.D.
Cardiac Surgery



Howard Song, M.D.
Cardiac Surgery



Kevin Wei, M.D.
Cardiovascular Imaging

www.ohsuknightheart.com

The knowledge of all for the care of **one**.

CAR 3068267 4/14